Revance Therapeutics, Inc.
RVNC · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $59,879 | $65,389 | $51,936 | $69,799 |
| % Growth | -8.4% | 25.9% | -25.6% | – |
| Cost of Goods Sold | $17,633 | $19,064 | $16,892 | $18,891 |
| Gross Profit | $42,246 | $46,325 | $35,044 | $50,908 |
| % Margin | 70.6% | 70.8% | 67.5% | 72.9% |
| R&D Expenses | $11,379 | $15,484 | $13,627 | $19,720 |
| G&A Expenses | $62,218 | $65,217 | $0 | -$169,128 |
| SG&A Expenses | $62,218 | $65,416 | $67,478 | $84,296 |
| Sales & Mktg Exp. | $0 | $123 | $0 | $253,424 |
| Other Operating Expenses | $905 | -$453 | -$438 | $218 |
| Operating Expenses | $74,502 | $80,900 | $81,105 | $104,016 |
| Operating Income | -$32,256 | -$34,575 | -$46,061 | -$53,108 |
| % Margin | -53.9% | -52.9% | -88.7% | -76.1% |
| Other Income/Exp. Net | -$4,359 | -$2,953 | -$2,698 | -$2,591 |
| Pre-Tax Income | -$36,615 | -$37,469 | -$49,525 | -$55,699 |
| Tax Expense | -$1,500 | $0 | $0 | $0 |
| Net Income | -$35,115 | -$37,473 | -$53,152 | -$55,699 |
| % Margin | -58.6% | -57.3% | -102.3% | -79.8% |
| EPS | -0.34 | -0.36 | -0.58 | -0.62 |
| % Growth | 5.6% | 37.9% | 6.5% | – |
| EPS Diluted | -0.34 | -0.36 | -0.58 | -0.62 |
| Weighted Avg Shares Out | 104,213 | 103,870 | 91,919 | 90,146 |
| Weighted Avg Shares Out Dil | 104,213 | 103,870 | 91,919 | 90,146 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,631 | $3,179 | $2,996 | $3,434 |
| Interest Expense | $6,732 | $5,679 | $5,256 | $5,398 |
| Depreciation & Amortization | $1,252 | $1,429 | $1,981 | $1,419 |
| EBITDA | -$28,631 | -$30,361 | -$42,288 | -$48,882 |
| % Margin | -47.8% | -46.4% | -81.4% | -70% |